Invention Grant
- Patent Title: Modified-IgG antibodies that bind transforming growth factor-BETA1 with high affinity, avidity and specificity
-
Application No.: US17717967Application Date: 2022-04-11
-
Publication No.: US11834495B2Publication Date: 2023-12-05
- Inventor: Huawei Qiu , Julie Bird
- Applicant: Genzyme Corporation
- Applicant Address: US MA Cambridge
- Assignee: Genzyme Corporation
- Current Assignee: Genzyme Corporation
- Current Assignee Address: US MA Cambridge
- Agency: Steptoe & Johnson LLC
- Agent Z. Ying Li; Mauricio Alvarez
- The original application number of the division: US15555500
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/22 ; C12N15/11
Abstract:
A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.
Public/Granted literature
Information query
